Central Nervous System Lymphoma
The sponsor’s clinical research activity is focused on primary central nervous system lymphoma, with particular attention to primary diffuse large B-cell lymphoma affecting the brain, leptomeninges, eyes, and spinal cord.
- Primary CNS lymphoma
- Diffuse large B-cell lymphoma
- Leptomeningeal involvement
- Ocular lymphoma
- Spinal cord lymphoma
The research interest lies in a rare non-Hodgkin lymphoma subtype with significant neurological involvement and limited therapeutic options.
Neuro-Oncology
Clinical work in neuro-oncology is directed toward malignancies confined to the central nervous system, where treatment planning must account for both tumor control and neurological preservation.
- Brain tumor oncology
- Neurological malignancies
- Central nervous system disease
- Rare brain tumors
This area reflects interest in cancers that overlap hematology and neurology, especially conditions with aggressive clinical behavior and complex anatomical constraints.
Hematologic Malignancies
The sponsor is involved in research on aggressive lymphoid malignancies, with emphasis on treatment approaches for high-grade disease biology and relapse prevention.
- High-grade lymphoma
- B-cell lymphoma
- Non-Hodgkin lymphoma
- Onco-hematology
Its therapeutic focus includes disease entities that require coordinated management across hematology, oncology, and transplant-related care.
Transplant-Integrated Therapy
Research activity also extends to autologous stem cell transplantation as part of treatment strategies for newly diagnosed central nervous system lymphoma.
- Autologous stem cell transplantation
- Consolidation therapy
- Intensive lymphoma treatment
- Multimodal cancer care
This therapeutic domain centers on combining systemic cancer treatment with transplant-based approaches in specialized hospital settings.
